Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation

This study has been completed.
Information provided by (Responsible Party):
Salix Pharmaceuticals Identifier:
First received: December 5, 2008
Last updated: August 29, 2014
Last verified: June 2011

This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.

Condition Intervention Phase
Drug: N-methylnaltrexone bromide (MOA-728)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain

Resource links provided by NLM:

Further study details as provided by Salix Pharmaceuticals:

Primary Outcome Measures:
  • collection of safety data & assessments to include monitoring of treatment emergent adverse events, safety laboratory measurements, electrocardiograms and changes in the physical exam including vital signs while on therapy [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • change in bowel function compared to baseline [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 1040
Study Start Date: December 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: N-methylnaltrexone bromide (MOA-728)
48 week treatment with 12 mg MOA-728 administered subcutaneously at least once per week with a maximum frequency of once daily.
Other Name: Relistor


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • men and women 18 years or older,
  • history of pain of at least 2 months duration before study entry due to documented underlying nonmalignant condition,
  • history of constipation due to opioid use for the nonmalignant condition,

Exclusion Criteria:

  • diagnosis of significant GI disorder such as bowel obstruction, fecal incontinence or rectal prolapse for example,
  • history of active inflammatory bowel disease, irritable bowel syndrome, or megacolon within 6 months before study entry,
  • history of malignancy or chronic constipation before initiation of opioid therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00804141

  Show 120 Study Locations
Sponsors and Collaborators
Salix Pharmaceuticals
Study Director: James Joffrion Salix Pharmaceuticals
  More Information

Additional Information:
No publications provided

Responsible Party: Salix Pharmaceuticals Identifier: NCT00804141     History of Changes
Other Study ID Numbers: 3200K1-3358
Study First Received: December 5, 2008
Last Updated: August 29, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Salix Pharmaceuticals:
treatment for opioid-induced constipation

Additional relevant MeSH terms:
Signs and Symptoms
Signs and Symptoms, Digestive
Central Nervous System Agents
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on March 03, 2015